[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"stage-b-heart-failure\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:stage-b-heart-failure":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,52],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":21,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":28,"overallStatus":39,"whyStopped":4,"lastUpdateSubmitDate":40,"lastUpdatePostDateStruct":41,"startDateStruct":44,"completionDateStruct":46,"leadSponsor":48,"locationsCount":51},"100652212","cardioprotective-effects-of-sglt2-inhibitors-and-glp-1-receptor-agonists-in-korean-patients-with-type-2-diabetes-100652212",false,"NCT07770737","Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes","Evaluation of Cardioprotective Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists in Korean Patients With Type 2 Diabetes: A Multicenter CDM-Based Retrospective Cohort Study With Prospective AI-ECG Validation","Phase 1: Retrospective Cohorts\n\nInclusion Criteria:\n\n* Adults aged 19 years or older.\n* Diagnosis of type 2 diabetes mellitus.\n* New initiation of a study medication, including an SGLT2 inhibitor, a GLP-1 receptor agonist, or another eligible glucose-lowering medication.\n* At least 180 days of observable data before the index date, defined as the date of the first eligible prescription.\n\nExclusion Criteria:\n\n* Type 1 diabetes mellitus or secondary diabetes mellitus.\n* Use of a medication from the same drug class within 90 days before the index date.\n* Pregnancy recorded during the relevant study period.\n* A history of the outcome being evaluated during the baseline period, applied separately for each outcome analysis.\n\nPhase 2: Prospective SGLT2 Inhibitor Validation Cohort\n\nInclusion Criteria:\n\n* Adults aged 50 years or older receiving outpatient care at Dongtan Sacred Heart Hospital.\n* Diagnosis of type 2 diabetes mellitus.\n* No current or previous signs or symptoms of heart failure and New York Heart Association functional class I.\n* At least one of the following high-risk characteristics: diabetes duration of 5 years or longer, hypertension, body mass index of 25 kg\u002Fm² or higher, urinary albumin-to-creatinine ratio of 30 mg\u002Fg or higher, estimated glomerular filtration rate below 60 mL\u002Fmin\u002F1.73 m², or diabetic microvascular complications.\n* No previous treatment with an SGLT2 inhibitor and scheduled to initiate an SGLT2 inhibitor based on the treating physician's clinical judgment.\n* Ability and willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Current or previous diagnosis of heart failure, hospitalization for heart failure, clinically suspected signs or symptoms of heart failure, or screening left ventricular ejection fraction below 50%.\n* Moderate or severe valvular heart disease, known hypertrophic, dilated, or infiltrative cardiomyopathy, complex congenital heart disease, or clinically significant pericardial disease.\n* Acute coronary syndrome, coronary revascularization, or stroke within 3 months before enrollment.\n* Presence of a pacemaker, implantable cardioverter-defibrillator, or cardiac resynchronization therapy device.\n* Atrial fibrillation, sustained tachycardia, frequent premature contractions, or another arrhythmia that prevents reliable comparison of ECG or global longitudinal strain measurements.\n* Type 1 diabetes mellitus, secondary diabetes mellitus, diabetic ketoacidosis within the previous year, or another clinical condition making SGLT2 inhibitor treatment inappropriate.\n* Estimated glomerular filtration rate below 30 mL\u002Fmin\u002F1.73 m² or dialysis.\n* Echocardiographic image quality insufficient for reliable 3-view global longitudinal strain or stage B heart failure assessment.\n* Pregnancy or breastfeeding.\n* Unwillingness to undergo study assessments or inability to complete the 6-month follow-up.","ALL","19 Years",{"count":19,"type":20},100,"ESTIMATED","6 Months","OBSERVATIONAL","This observational study will evaluate the cardiovascular effects of sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) and glucagon-like peptide-1 receptor agonists (GLP-1 receptor agonists) in Korean adults with type 2 diabetes.\n\nThe study consists of two phases. Phase 1 will use de-identified electronic health record data from multiple Korean hospitals organized in a common data model. Cardiovascular outcomes, including myocardial infarction, ischemic stroke, and hospitalization for heart failure, will be compared among patients who started an SGLT2 inhibitor or a GLP-1 receptor agonist. Fractures, metabolic changes, and real-world medication use will also be evaluated.\n\nPhase 2 will prospectively enroll approximately 100 adults with type 2 diabetes who are starting an SGLT2 inhibitor as part of routine clinical care at Dongtan Sacred Heart Hospital. Participants will undergo electrocardiography, AI-based ECG analysis, echocardiography, blood and urine tests, and body composition assessment at baseline. Approximately 50 participants with stage B heart failure, defined as structural or functional heart abnormalities without heart failure symptoms, will undergo the same assessments after 6 months. The primary outcome of Phase 2 is the change in echocardiographic global longitudinal strain from baseline to 6 months. The study will also examine whether changes detected by AI-based ECG are associated with changes in echocardiographic measures of cardiac function.\n\nThe study does not assign medications or alter routine treatment. All treatment decisions are made by the participants' treating physicians.",[25,26,27],"Type 2 Diabetes Mellitus (T2DM)","Cardiovascular Diseases","Stage B Heart Failure",[29,30,31,32,33,34,35,27,36,37,38],"SGLT2 Inhibitor","GLP-1 Receptor Agonist","Cardiovascular Protection","Artificial Intelligence Electrocardiography","AI-ECG","Global Longitudinal Strain","Diabetic Cardiomyopathy","Pre-Heart Failure","OMOP Common Data Model","Real-World Data","NOT_YET_RECRUITING","2026-08-13",{"date":42,"type":43},"2026-08-18","ACTUAL",{"date":45,"type":20},"2026-09",{"date":47,"type":20},"2027-12-31",{"name":49,"class":50},"Dongtan Sacred Heart Hospital","OTHER",1,{"id":53,"slug":54,"hasResults":11,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":58,"eligibilityCriteria":59,"healthyVolunteers":11,"sex":16,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":64,"conditions":65,"keywords":68,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":51},"100607172","determination-of-the-prevalence-of-unrecognized-heart-failure-among-patients-at-risk-in-urban-areas-across-germany-using-cmr-100607172","NCT07185100","Determination of the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR","A Prospective, Cross-sectional, Nationwide Community-based Observational Study to Determine the Prevalence of Unrecognized Heart Failure Among Patients at Risk in Urban Areas Across Germany Using CMR","WE-CARE-HF-CMR","Inclusion Criteria:\n\nAsymptomatic subjects with:\n\n* chronic diabetes mellitus (known\u002Fdiagnosed and\u002For antidiabetic medication and\u002For elevated HbA1C) and\u002For\n* renal impairment (known\u002Fdiagnosed CKD and\u002For in laboratory CKD III° or higher) and\u002For\n* Hypertension (known\u002Fdiagnosed and\u002For antihypertensive medication\u002Ftreatment) and\u002For\n* Hypercholesterolaemia (known\u002Fdiagnosed and\u002For antilipid medication\u002Ftreatment) and\u002For\n* Obesity (known\u002Fdiagnosed and\u002For BMI \\> 30 (kg\u002Fm²)) and\u002For\n* Smoker (known\u002Fdiagnosed and\u002For current\u002Fprevious and\u002For medication\u002Ftreatment)\n* Age 40-69 years\n* female or male or diverse sex\n* Ability to provide informed consent\n* Provision of Informed Consent\n\nExclusion Criteria:\n\n* Inability to provide written informed consent\n* Diagnosed heart failure or previously detected reduced ejection fraction\n* General MRI exclusion criteria (pacemaker, defibrillator, intracranial aneurysm clips, metallic foreign bodies in the eyes)\n* Any MRI exclusion criteria not listed here, as determined by the MRI laboratory performing the procedure\n* Haemodynamically unstable participants (heart rate \\\u003C 45\u002Fmin, systolic blood pressure \\\u003C 90 mmHg)\n* Claustrophobia\n* Sensorineural hearing loss of 30 dB or more and tinnitus\n* Acute mental disorders requiring therapy\n* In the presence of pregnancy","40 Years","69 Years",{"count":63,"type":20},600,"Heart failure (HF) in patients at risk is often overlooked, and when detected, there is a lack of early and effective preventive interventions. The WE-CARE-HF-CMR study, conducted in large cities\u002Fmetropol areas in Germany ( \\> 1.000.000 inhabitants), aims to close this gap by evaluating the feasibility of a mobile, telemedicinemonitored HF-screening approach combining cardiac magnetic resonance imaging (CMR), quality of life assessment and laboratory tests as key elements in asymptomatic patients at risk. WE-CARE-HF-CMR will provide a proposal for a comprehensive, contemporary screening approach for patients at risk to develop HF tailored to the needs of the target population. This will provide important new information on the prevalence of asymptomatic HF in at-risk patients in urban versus rural areas.\n\nThe results of the study will be compared with the results from the \"HERZCheck'' trial, which provides data from approximately 4,500 participants in rural areas in Germany and has already been completed (NCT05122793).",[66,67,27],"Heart Failure With Preserved Ejection Fraction (HFPEF)","Renal Dysfunction",[69,70,71,72,73,74,75,76,77,78,79,80,81,82],"Prevention","Heart failure","HFpEF","Asymptomatic","Cardiology","Urban area","Germany","CMR","Cardiac Magnetic Resonance","HFrEF","Diastolic Dysfunction","Strain","mobile","GLS","RECRUITING","2026-03-26",{"date":86,"type":43},"2026-04-01",{"date":88,"type":43},"2025-09-13",{"date":90,"type":20},"2036-12-31",{"name":92,"class":50},"German Heart Institute"]